secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZYNEX INC (—)
CIK:        0000846475
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001558370-24-006269
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zynex Q1 revenue up 10% to $46.5M; net income near zero; orders up 23% YoY
--------------------------------------------------------------------------

- Q1 revenue $46.5M (+10% YoY); missed $47.5M guidance due to cyber incident delaying insurer payments; full-year $227M guide reaffirmed.
- Net income $10,000 ($0.00 diluted EPS); adjusted EBITDA $1.7M; orders hit eighth consecutive quarterly record, up 23% YoY.
- Repurchased $13.4M of stock in Q1; $78.5M over past 24 months.
- FDA clearance for next-gen M-Wave NMES device; launched Zynex Pro Hybrid LSO and DynaComp Cold Compression therapy products.
- Q2 guidance: revenue at least $52M, diluted EPS at least $0.08; FY 2024: revenue at least $227M, diluted EPS at least $0.50.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/846475/000155837024006269/0001558370-24-006269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/846475/000155837024006269/zyxi-20240430x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer